Comprehensive analysis of UTI-Healthcare Fund (G) (2624) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
UTI Asset Management Company Ltd
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Moderate Returns
High Risk
High Expenses
Equity Focused
Experienced Team
Below Average
Showing 1Y NAV history
Performance across different time periods
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Fund manager experience
Market exposure level
Recent performance momentum
Historical performance consistency
Risk-adjusted returns
Assets under management
Fund management costs
Outperformance vs benchmark
This fund has outperformed its benchmark by 12.40% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 9.84% |
| Cipla Ltd | Pharmaceuticals | 5.43% |
| Ajanta Pharma Ltd | Pharmaceuticals | 4.80% |
| Lupin Ltd | Pharmaceuticals | 4.29% |
| Procter & Gamble Health Ltd | Pharmaceuticals | 4.13% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 3.99% |
| Glenmark Pharmaceuticals Ltd | Pharmaceuticals | 3.54% |
| Fortis Healthcare Ltd | Healthcare | 3.48% |
| Apollo Hospitals Enterprise Ltd | Healthcare | 3.47% |
| Gland Pharma Ltd | Pharmaceuticals | 3.01% |
Compare against Sectoral / Thematic category average
This comparison shows how the fund performs relative to the Sectoral / Thematic category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Sectoral / Thematic category
| Fund Name | NAV | 6M | 1Y | 3Y |
|---|---|---|---|---|
| Aditya Birla SL MNC Fund - Direct (G) | ₹1540.61 | 20.90% | -2.29% | 13.00% |
| Aditya Birla SL MNC Fund - (G) | ₹1383.22 | 20.48% | -2.95% | 12.20% |
| Nippon India Banking&Financial Services-Dir(G) | ₹662.94 | 13.57% | 4.61% | 17.80% |
| Nippon India Banking&Financial Services-Dir(Bonus) | ₹662.94 | 13.57% | 4.61% | 17.80% |
| Nippon India Banking&Financial Services (G) | ₹606.00 | 13.09% | 3.74% | 16.83% |
| Nippon India Banking&Financial Services (Bonus) | ₹606.00 | 13.09% | 3.74% | 16.83% |
| Nippon India Pharma Fund - Direct (G) | ₹574.98 | 13.30% | 0.45% | 24.37% |
| Nippon India Pharma Fund - Direct (Bonus) | ₹574.98 | 13.30% | 0.45% | 24.37% |
| Franklin India Technology Fund - Direct (G) | ₹565.29 | 7.85% | -5.66% | 23.50% |
| ICICI Pru FMCG Fund - Direct (G) | ₹542.41 | 13.18% | -7.36% | 10.35% |
A seasoned investment professional with over 26 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.